Registration - Consultant

Novartis Pharmaceuticals Canada, Inc. / Roberta Kramchynsky, Consultant

Registration Information

Client name: Novartis Pharmaceuticals Canada, Inc.
Lobbyist name: Roberta Kramchynsky, Consultant
Initial registration start date: 2010-04-07
Registration status: Inactive
Registration Number: 782631-265342

Associated Communications

Total Number of Communication Reports: 0

Monthly communication reports in the last 6 months: 0

Version 1 of 6 (2010-04-07 to 2010-08-18)

Registration versions:

Version 1 of 6 (2010-04-07 to 2010-08-18)

Lobbying Information

Subject Matters

Aboriginal Affairs
Consumer Issues
Environment
Health
Industry
Intellectual Property
International Relations
International Trade
Science and Technology
Taxation and Finance

Subject Matter Details

Legislative Proposal, Bill or Resolution

Food and Drugs Act, specifically with respect to the approval, regulation and life-cycle management of therapeutic products and legislative modernization
Patent Act with respect to Canada's Access to Medicines Regime (ss. 21.01-21.09)

Legislative Proposal, Bill or Resolution, Regulation

Canada's Food and Consumer Safety Action Plan, specifically proposed legislation and regulation with respect to therapeutic products and consumer products

Policies or Program

Canadian Agency for Drugs and Technologies in Health policies with respect to the Common Drug Review, Health Technology Assessment and the Canadian Optimal Medication Prescribing and Utilization Service
Federal Health Partnership with respect to the coordination of federal drug plan policies and programs
Federal public drug plans, specifically the Non-Insured Health Benefits Program (Health Canada), with respect to decisions and policies that impact reimbursement of therapeutic products for plan beneficiaries
Industry Canada policies related to research and development of treatments for rare disorders
International Trade Canada's Invest in Canada policies and programs with respect to investment, business development and innovation in the life sciences industry sector
Orphan drug policy to address treatment for rare disorders
Patented Medicines Prices Review Board with respect to excessive price guidelines
Science and Technology Strategy led by Industry Canada, particularly with respect to the life sciences priority under the S&T Strategy

Regulation

Food and Drugs Act Regulations, specifically with respect to approval, regulation and life-cycle management of therapeutic products and Data Protection under section C.08.004
Patent Act Regulations as they relate to the regulation of intellectual property for therapeutic products, specifically with respect to the Patented Medicines (Notice of Compliance) Regulations
Patent Act as it relates to the regulation of intellectual property for therapeutic products

Communication Techniques

Written communication
Oral communication

The lobbyist has arranged or expects to arrange one or more meetings on behalf of the client between a public office holder and any other person in the course of this undertaking.

Government Institutions

Foreign Affairs and International Trade Canada (DFAITC)
Health Canada (HC)
House of Commons
Industry Canada
Patented Medicine Prices Review Board (PMPRB)
Public Health Agency of Canada (PHAC)
Senate of Canada

Client Details

Government funding

No government funding was received during the last completed financial year.

Client Contact Information

Address:
385 Bouchard Boul.
Dorval, QC H9S 1A9
Canada

Telephone number: 514-631-6775

Client representative

Alain Boisvert, Director, Public Policy

Parent Company Information

Novartis International AG
- CH-4002
  Basel CH-4002
  Switzerland

Coalition Members Information

Novartis Pharmaceuticals Canada, Inc. is not a coalition.

Individual, organization or corporation with a Direct Interest Beneficiary Information

The activities of Novartis Pharmaceuticals Canada, Inc. are not controlled or directed by another individual, organization or corporation with a direct interest in the outcome of this undertaking.

Subsidiary Beneficiary Information

Novartis Pharmaceuticals Canada, Inc. does not have any subsidiaries that could have a direct interest in the outcome of the undertaking

Lobbyist Details

Roberta Kramchynsky | Public offices held

Business address:
50 O'Connor - Suite 901
Ottawa, ON K1P 6L2
Canada

Telephone number: 613-783-3438

Consultant Firm and Address

Firm: Global Public Affairs

Address:
50 O'Connor - Suite 901
Ottawa, ON K1P 6L2
Canada

Telephone number: 613-783-2336

Novartis Pharmaceuticals Canada, Inc.

The following names have been used on or after July 2, 2008

Name	From	To
Novartis Pharmaceuticals Canada, Inc.	2010-04-07	2013-12-02

Novartis Pharmaceuticals Canada, Inc.

Responsible Officer History
Responsible Officer Name	From (YYYY-MM-DD)	To (YYYY-MM-DD)

List of Public Offices Held
Position	Period Held	Last Date Designated Public Office Held
Special Assistant House of Commons, Office of Ted Menzies, MP	September 2006 to November 2007	Not a designated office
Member's Assistant House of Commons, Office of Hon. Carol Skelton, PC, MP	February 2006 to July 2006	Not a designated office
Administrative Assistant House of Commons, Office of the Leader of the Opposition	September 2004 to January 2006	Not a designated office

List of Public Offices Held
Position	Period Held	Last Date Designated Public Office Held
Special Assistant House of Commons, Office of Ted Menzies, MP	September 2006 to November 2007	Not a designated office
Member's Assistant House of Commons, Office of Hon. Carol Skelton, PC, MP	February 2006 to July 2006	Not a designated office
Administrative Assistant House of Commons, Office of the Leader of the Opposition	September 2004 to January 2006	Not a designated office

Date Modified:: 2025-06-03

Search and menus

Language selection

Registration - Consultant

Novartis Pharmaceuticals Canada, Inc. / Roberta Kramchynsky, Consultant

Registration Information

Associated Communications

Version 1 of 6 (2010-04-07 to 2010-08-18)

Version 1 of 6 (2010-04-07 to 2010-08-18)

Subject Matters

Subject Matter Details

Legislative Proposal, Bill or Resolution

Legislative Proposal, Bill or Resolution, Regulation

Policies or Program

Regulation

Communication Techniques

Government Institutions

Government funding

Client Contact Information

Client representative

Parent Company Information

Coalition Members Information

Individual, organization or corporation with a Direct Interest Beneficiary Information

Subsidiary Beneficiary Information

Consultant Firm and Address